Bayer de Mexico, S.A. de C.V.December 9, 2022

FDA 483 - Bayer de Mexico, S.A. de C.V. - December 09, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bayer de Mexico, S.A. de C.V.

Record Details

Bayer de Mexico, S.A. de C.V., a drug manufacturer in Lerma, Mexico, was cited for deficiencies related to its quality control unit and reserve sample management. The firm failed to adequately control GxP worksheets and assess product quality impact from deviations. Additionally, the inspection found issues with the annual visual examination, reporting, and secondary review of reserve samples for drug products.

Company: Bayer de Mexico, S.A. de C.V.
Inspection Date: December 9, 2022
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
People: Alan L. Truong
Maria Estrella (investigator)

Open in Dashboard

ID · 8d6686bf-90a9-434c-8630-bb08bd31c656